CY1122060T1 - Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων - Google Patents

Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων

Info

Publication number
CY1122060T1
CY1122060T1 CY20191100598T CY191100598T CY1122060T1 CY 1122060 T1 CY1122060 T1 CY 1122060T1 CY 20191100598 T CY20191100598 T CY 20191100598T CY 191100598 T CY191100598 T CY 191100598T CY 1122060 T1 CY1122060 T1 CY 1122060T1
Authority
CY
Cyprus
Prior art keywords
antibodies
endoglycosidases
therapeutic
therapeutic antibody
therapeutic use
Prior art date
Application number
CY20191100598T
Other languages
English (en)
Inventor
Matthew David Max Crispin
Christopher Neil SCANLAN
Original Assignee
Immago Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immago Biosystems Ltd filed Critical Immago Biosystems Ltd
Publication of CY1122060T1 publication Critical patent/CY1122060T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση σχετίζεται με συνθέσεις που περιλαμβάνουν θεραπευτικά αντισώματα, καθώς και με χρήσεις και μεθόδους για την αύξηση της ισχύος των θεραπευτικών αντισωμάτων. Ειδικότερα, η εφεύρεση παρέχει μια σύνθεση η οποία περιλαμβάνει (i) μια ουσία που μειώνει τη δέσμευση του υποδοχέα του Fc των ενδογενών αντισωμάτων ορού και (ii) ένα θεραπευτικό αντίσωμα, κατά προτίμηση ένα θεραπευτικό αντίσωμα το οποίο είναι ανθεκτικό στην ουσία. Το θεραπευτικό αντίσωμα μπορεί να χορηγηθεί στο υποκείμενο μετά από ένα ορισμένο χρονικό διάστημα ή το αίμα του υποκειμένου μπορεί να υποβληθεί σε κατεργασία με την ουσία πριν από τη χορήγηση του θεραπευτικού αντισώματος.
CY20191100598T 2012-01-26 2019-06-06 Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων CY1122060T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201201314A GB201201314D0 (en) 2012-01-26 2012-01-26 Composition
PCT/GB2013/050164 WO2013110946A1 (en) 2012-01-26 2013-01-25 Combined therapeutic use of antibodies and endoglycosidases

Publications (1)

Publication Number Publication Date
CY1122060T1 true CY1122060T1 (el) 2020-11-25

Family

ID=45840985

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100598T CY1122060T1 (el) 2012-01-26 2019-06-06 Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων

Country Status (17)

Country Link
US (4) US20150125443A1 (el)
EP (1) EP2806892B1 (el)
JP (1) JP6249962B2 (el)
CN (2) CN108619509A (el)
CY (1) CY1122060T1 (el)
DK (1) DK2806892T3 (el)
ES (1) ES2728290T3 (el)
GB (1) GB201201314D0 (el)
HR (1) HRP20191022T1 (el)
HU (1) HUE044632T2 (el)
IN (1) IN2014DN06722A (el)
LT (1) LT2806892T (el)
PL (1) PL2806892T3 (el)
PT (1) PT2806892T (el)
SI (1) SI2806892T1 (el)
TR (1) TR201908367T4 (el)
WO (1) WO2013110946A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
GB201318490D0 (en) * 2013-10-18 2013-12-04 Genovis Ab Method
EP3904388A1 (en) 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
EP3154582A4 (en) 2014-05-28 2018-01-10 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
EP3323886B1 (en) * 2015-07-16 2020-10-21 Daiichi Sankyo Company, Limited Endos mutant enzyme
AU2017212484C1 (en) * 2016-01-27 2020-11-05 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
JP2019527192A (ja) 2016-05-31 2019-09-26 カーディオバックス リミテッド ライアビリティ カンパニー 全身性エリテマトーデスの診断及び治療方法
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP2017226648A (ja) * 2016-06-17 2017-12-28 ＳｏｎｏＣｏｒｅ株式会社 分子標的薬バブルおよび分子標的薬バブルの製造方法
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN110151987B (zh) * 2018-02-11 2023-10-13 汕头大学医学院 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途
US20230049145A1 (en) * 2019-12-12 2023-02-16 Fresenius Kabi Deutschland Gmbh Glycosylated polypeptides
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
US20230277633A1 (en) * 2020-06-05 2023-09-07 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical composition of enzymes and viruses and application thereof
CN113769058A (zh) * 2020-06-10 2021-12-10 上海宝济药业有限公司 一种药物组合及其应用
US20230374083A1 (en) * 2020-09-21 2023-11-23 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof
WO2022124096A1 (ja) * 2020-12-11 2022-06-16 東ソー株式会社 免疫グロブリン結合糖鎖の予測方法
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040136986A1 (en) 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP2319935B1 (en) 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
WO2004007499A1 (en) 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
EP2190984B1 (en) * 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
EP3904388A1 (en) * 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same

Also Published As

Publication number Publication date
CN104519911A (zh) 2015-04-15
GB201201314D0 (en) 2012-03-07
LT2806892T (lt) 2019-07-25
ES2728290T3 (es) 2019-10-23
US20230398212A1 (en) 2023-12-14
JP6249962B2 (ja) 2017-12-20
EP2806892B1 (en) 2019-03-06
TR201908367T4 (tr) 2019-06-21
US20200345844A1 (en) 2020-11-05
HUE044632T2 (hu) 2019-11-28
PT2806892T (pt) 2019-06-17
IN2014DN06722A (el) 2015-05-22
HRP20191022T1 (hr) 2019-09-06
WO2013110946A1 (en) 2013-08-01
CN104519911B (zh) 2018-07-17
SI2806892T1 (sl) 2019-08-30
DK2806892T3 (da) 2019-06-11
US20150125443A1 (en) 2015-05-07
EP2806892A1 (en) 2014-12-03
JP2015511223A (ja) 2015-04-16
US20170274070A1 (en) 2017-09-28
PL2806892T3 (pl) 2019-09-30
CN108619509A (zh) 2018-10-09

Similar Documents

Publication Publication Date Title
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
EA201600190A1 (ru) Анти-prlr антитела и их применение
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201592203A1 (ru) Способы лечения таупатии
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso